Biohaven Pharmaceutical Holding Co Ltd (NASDAQ:BHVN) has earned an average rating of “Buy” from the seven analysts that are covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $39.50.

BHVN has been the subject of a number of analyst reports. Zacks Investment Research raised shares of Biohaven Pharmaceutical Holding Co from a “sell” rating to a “hold” rating in a report on Monday, August 28th. BidaskClub raised shares of Biohaven Pharmaceutical Holding Co from a “buy” rating to a “strong-buy” rating in a report on Thursday, September 28th. Morgan Stanley reissued an “overweight” rating and issued a $38.00 price target (down previously from $47.00) on shares of Biohaven Pharmaceutical Holding Co in a report on Tuesday, October 3rd. Needham & Company LLC reissued a “buy” rating and issued a $43.00 price target (up previously from $30.00) on shares of Biohaven Pharmaceutical Holding Co in a report on Wednesday, September 13th. Finally, William Blair reissued an “outperform” rating on shares of Biohaven Pharmaceutical Holding Co in a report on Tuesday, October 3rd.

COPYRIGHT VIOLATION WARNING: “Brokerages Set Biohaven Pharmaceutical Holding Co Ltd (BHVN) PT at $39.50” was first published by Watch List News and is owned by of Watch List News. If you are reading this story on another site, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The legal version of this story can be viewed at https://www.watchlistnews.com/brokerages-set-biohaven-pharmaceutical-holding-co-ltd-bhvn-pt-at-39-50/1618366.html.

Biohaven Pharmaceutical Holding Co (NASDAQ:BHVN) traded up 0.12% during midday trading on Thursday, hitting $32.10. The stock had a trading volume of 99,602 shares. Biohaven Pharmaceutical Holding Co has a one year low of $17.00 and a one year high of $39.51. The stock’s 50-day moving average is $35.99 and its 200-day moving average is $27.79. The company’s market cap is $1.15 billion.

Biohaven Pharmaceutical Holding Co Company Profile

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Analyst Recommendations for Biohaven Pharmaceutical Holding Co (NASDAQ:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Holding Co Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical Holding Co Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.